CXCL9 and neoplasm: During anti-tumor responses, CD8 effector T cells readily infiltrate B16F10 tumors in a CXCR3-dependent manner in response to CXCL9 and/or CXCL10 expressed by both tumor cells and CD11c+ cells (48, 49).